Key facts
as of Oct 2026- Developer of an advanced technology platform designed to aid drug developers in crafting innovative drug candidates.
- Meddenovo Drug Design is valued at approximately $6.8M as of Oct 2026 (last reported valuation).
- It has raised $1.0M; the latest was Early Stage VC ($470K) in Jul 2025.
- Notable investors include Turkey Development Fund, ACT Venture Partners.
- Status: Privately Held (backing).
Meddenovo Drug Design's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·Watch Meddenovo Drug Design: the Monday email on marks, rounds and moves
Funding rounds
No funding rounds for Meddenovo Drug Design are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Meddenovo Drug Design
Developer of an advanced technology platform designed to aid drug developers in crafting innovative drug candidates. The company's platform is uniquely optimized for the design of cyclic peptides, utilizing a seamless blend of artificial intelligence and physical computational techniques, Cyclic peptides hold tremendous promise as therapeutic agents for a wide range of diseases that currently lack effective treatments and despite their potential, the development of peptide-based drugs has been hindered by the absence of specialized design tools. enabling businesses to provide improved robust technology which requires minimal expertise.
- Sector
- Healthcare
- HQ
- Villeurbanne, France
- Founded
- 2023
- Employees
- 7
- Website
- meddenovo.com/
- Ownership
- Privately Held (backing)